Covidplay
BA Breakout and My Trading PlanBoeing is looking to breakout the downtrend here. It has been doing this pattern and breakouts ever since the covid crash and we have another instance here. BA has consistently been creating these downward wedge patterns and breaking out.
With the increase in vaccinations and covid issues starting to decline, and businesses and travel opening back up, this could be the catalyst that BA needs to start going back up. The USA also are now allowing vaccinated foreigners into the country which is huge for tourism.
I will be playing the gap fill at around 230$ - 235$, which would be my TARGET #1
There is also GAP #2 at around 245$ which could be the second target if it breaks the 230$ and the 240$
BEWARE: we did create a gap below, and is very possible that we fill that gap below before we can rip higher
OPTIONS:
I would take a month out, if more for these contracts. The Dec 3rd have decent open interests on the 225C and the 230C
DEC 17th look the best however with over 10k Open interest in many different contracts.
GOOD LUCK!
PTON - CEO dumped 100k shares Aug 20Earnings is Aug 26th. 1. The CEO just dumped 1/3 (100,000) of his shares Friday Aug 20th, leaving him with 200k shares. 2. Weekly chart - Bearish Head and shoulders pattern. 3. Earnings - Last quarter, they beat EPS and revenue, but guided revs lower for next Q. Most of USA was open during this quarter, probably less sales. I think if there is another lockdown, PTON will pick up in the next quarter. So, if you want to go long, wait for after this ER. $82 area would be good entry. 4. Options flow - There are over 15k $100 puts and some calls in 110, 120 strike. The put call ratio is 1.16 (bearish).
SRNE News....Key AreaThis could be an important area for SRNE right now. You've got Fibs and major moving averages all converging at the same point. News today:
"Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate website to provide an overview of Sorrento’s proprietary mRNA vaccine development program for COVID-19."
The presentation can be viewed at: investors.sorrentotherapeutics.com
Funny to think this was just a penny stock not that long ago:
Sorrento Therapeutics Inc. (SRNE Stock Report) is actually still one of the popular stocks on Robinhood this month. Compared to where it was trading in March, 2020, SRNE stock is trading at levels night and day different this month. In fact, SRNE stock hasn’t been considered a penny stock since the end of June. The range has gone from lows of $1.55 to highs of $19.39 so far.
Quote Source & Read More: Are Penny Stocks Worth It? 5 That Hit It Out Of The Park In 2020
SPY overlay China's 2015 retail boom-bust - In 2015 China had a retail boom-bust 🔥
- It did not take long for retail to find out who
was going to hold that bag 💰
- Covid, tech, and monetary policy in the US have conspired
to create another retail frenzy ⛈
- I attempt to overlay 2015's fundamentals, technicals, and psychology
to the current scenario 🏹
- Just a little observation and thought-experiment 💚
- Have fun out there!
someone is going to find that top 😬
BIOV -- FDA approval for COVID-19 clinical trialsBiotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study:
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.
The FDA found the Chemistry, Manufacturing and Controls, and other elements of the clinical development program proposed by BioVaxys to be acceptable and provided guidance and feedback supportive of BioVaxys' clinical development plans for CoviDTH. In addition, the FDA indicated that animal toxicity studies for CoviDTH were not required and that the Company could start its clinical development program with a combined Phase I/II study. Based on this feedback, BioVaxys will begin preparation of an IND application to support a Phase I/II safety, dosing, and efficacy study.
BioVaxys submitted a Pre-Investigational New Drug ("IND") meeting request and briefing package with the FDA's Center for Biologics Evaluation and Research (CBER) for CoviDTH earlier this year. The Pre-IND review is a critical step in the US regulatory approval process, as it affords an opportunity for study sponsor companies to seek clarification from the FDA on clinical trials design, clinical materials manufacturing, quality controls, etc.
"With the guidance we received from this FDA review, BioVaxys is now able to begin preparing its IND," stated BioVaxys President and Chief Operating Officer Ken Kovan. He adds "Although the FDA has indicated that our planned animal tox study is discretionary, we will likely continue with the animal tox study of CoviDTH as it does not interfere with the development time frame and may in fact provide useful data."
James Passin, BioVaxys CEO, stated, "We are pleased to advance CoviDTH towards clinical trials, as we believe that mass screening for T cell immunity to Covid-19 will represent a critical tool for public health authorities to address the continued pandemic, as Covid variants continue to circulate and major governments in the southern hemisphere enact new lockdown policies."
The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain Covid-19 (SARS-CoV-2) at this time.
Between Two Fibs - AEMDAEMD seems to like this range between the 786 and 618 fib lines. The 618 has long-been a point of resistance on the chart. Meanwhile, the last few days have seen it test the 786 level but hold both above it AND its 50DMA. No news today but focus on biotechs thanks to CYTK earlier could be a sympathy trigger at play. Also with the Delta varient becoming "a thing," covid stocks in numerous stages of development are becoming more of a focus right now. We'll have to see if 786 fib+ 50DMA post a strong support level and if 618 will remain resistance if or when AEMD takes another swing at it.
Biotech - CSLModel has given entry signals for CSL Limited:
- CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.
- We are very excited about opportunities in the biotech sector, as we believe the fight against COVID is going to move to the next phase in the nearest future.
- Technically in a Wyckoff accumulation structure with a spring, possibly testing the channel top.
GLHF,
DPT
Disclaimer:
We absolutely do not provide financial advice in any shape or form. We do not recommend investing based on our opinions and strongly cautions that securities trading and investment involves high risk and that you can lose a lot of money. Loss of principal is possible. We do not recommend risking money you cannot afford to lose. We do not guarantee future performance nor accuracy in historical analyses. We are not registered investment advisors. Our ideas, opinions and statements are not a substitute for professional investment advice. We provide ideas containing impersonal market observations and our opinions. Our speculations may be used in preparation to form your own ideas.
KNR -- Oversold; Double Bottom at .89. On watch for a bounce.KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open market. Share buyback program is in effect. Bullish MACD divergence on the chart.
UPI -- Fundamentally undervalued; multi-bagger candidate!UPI is ridiculously undervalued at $15M mkt cap and is a potential multi-bagger candidate from these levels.
- Close to $10M in revenue in 2020 and is on pace to at least double it — recorded $1M in sales in the first week of June!
- Profitable, no debt
- Exclusive distributor of the 20-second non-invasive (finger scan) COVID-19 test that is currently undergoing clinical trial at Toronto Pearson Airport and could be a game changer!
- Other products include COVID-19 virus elimination tech using UV lights, thermal detection and air filtration
- Expanding to the US
- Insiders are buying in the open market
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.
Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines)
Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful
Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox
finance.yahoo.com
$SPCB Wins COVID-19 Quarantine Project $3 Million per MonthSuperCom Wins COVID-19 Quarantine Compliance Project with the Israeli Government Valued at an Estimated $3 Million per Month in Recurring Revenues
Initial project term of 3 months, with potential extension for up to 36 months
This nationwide project is expected to commence next week, along with contract signing, for an initial term of 3 months, with an option to be extended for up to 36 months. The project is billed at a per-unit per-day rate is expected to generate approximately $3 million per month in recurring revenues for SuperCom. However, revenue may increase or decrease based on actual usage.
finance.yahoo.com
Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients
The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers.
finance.yahoo.com
UPI.V - Breakout. 1-min rapid COVID-19 tests and much more.UPI is a fundamentally strong company with $10M in year revs and only $22M mkt cap.
They're selling various COVID-19 detection tech and are also in air sanitation business. Today's news adds to their portfolio nicely:
Universal PropTech Inc. Invests in and Secures defined Agency Rights for ISBRG Corp.'s SpotLight-19(C) Technology Designed to Detect Covid-19 Non-Invasively in Under One Minute
Toronto, Ontario--(Newsfile Corp. - February 18, 2021) - Universal PropTech Inc. (TSXV: UPI) ("UPI" or the "Company") is pleased to announce that it has completed an investment in ISBRG Corp. ("ISBRG") for a minority interest, and secured agency rights to their SpotLight-19© Technology.
ISBRG is a data analytics company which has developed the SpotLight technology platform designed to generate comprehensive health care data non-invasively within seconds at a nominal incremental cost per test. SpotLight-19© is non-invasive, and ISBRG is undertaking trials to determine efficacy in detecting Covid-19. In addition to its minority investment, UPI will act as the exclusive sales agent for the SpotLight-19© technology and other future platform offerings for the government and education sectors in Canada.
Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February
There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media.
$IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month.
iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores.
The company generates a majority of its revenue from its retail segment.
The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19.
www.benzinga.com
twitter.com
Panel is capable of detecting 99.99% of all SARS-CoV-2 virusesT2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus
Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis.
finance.yahoo.com
OCGN - how to play the COVAXIN news !OCGN:
What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative.
Ok lets talk shop – technical:
POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason.
Volume: average volume is 63M, last 2 days trading above 100M.
50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal)
4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions….
Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal.
The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high
Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+.
Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !!
FDGT will wait for a pullback before entering as the trend doesn’t look healthy
This is not a recommendation of any sort
Trader safe and be safe – we are the traders union and we trade by our own rules!
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19.
Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat.
TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19.
TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication.
finance.yahoo.com
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg
- Company secures next step to continue to build-out pipeline of assets.
- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19.
- Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement.
to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities.
The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.
Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19.
A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial.
finance.yahoo.com
Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
AditxtScore™ Immune Monitoring Service Operational on February 1AditxtScore™ Immune Monitoring Service Will be Operational on February 1st
Company Plans to Offer Service through Channel Partners
The initial application of the platform will be AditxtScore™ for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus.
We’re currently in discussions with labs, hospitals and other channel partners around the world interested in incorporating AditxtScore™ into their offerings.
finance.yahoo.com
Adamis Surges After Submitting Covid Drug to FDAAdamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19).
The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol.
Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity.
finance.yahoo.com
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine DevelopmentGeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development
announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19.
The Phase 1 grant, titled, “Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,” will support the ongoing design, construction and preclinical testing of GeoVax’s vaccine candidates in preparation for human clinical trials. The efficacy testing will be performed in collaboration with the University of Texas Medical Branch (UTMB).
Vaccines using the GV-MVA-VLP platform developed for other pathogens have proven to be efficacious with a single dose, having strong durability which would be a significant advantage for SARS-CoV-2 global vaccination campaigns.”
We are pleased to receive this Phase 1 SBIR funding award, which will supplement the internal resources allocated to our COVID-19 vaccine program and accelerate our progress toward human clinical trials.
finance.yahoo.com
XpresSpa Group Inc $XSPA - Investment idea 💡 This is not just a penny stock, but also a good investment for long term, however if you're not planning to hold for long term, then I suggest you to take profits on each target level.
--
Do your research and trade on your own risk!
